BT-001
Sponsors
Transgene, Better Therapeutics
Conditions
Diabetes Mellitus, Type 2Diabetes Type 2MelanomaMerkel Cell CarcinomaMerkel cell carcinoma (MCC)Metastatic CancerMetastatic/advanced soft tissue sarcoma (STS)Non Small Cell Lung Cancer
Phase 1
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
TerminatedNCT04725331
Start: 2021-02-25End: 2025-10-22Updated: 2025-11-21
A Phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone, and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or, easily injectable lymph nodes of metastatic/advanced solid tumors.
CompletedCTIS2024-518529-14-00
Start: 2021-02-26End: 2025-10-22Target: 30Updated: 2025-08-26
Phase 3
Unknown Phase
Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy
NCT05266625
Start: 2022-02-14End: 2025-11-30Updated: 2023-10-30
A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus
NCT05302050
Start: 2022-03-07End: 2025-12-01Updated: 2023-10-30